While 2-DG has not yet been approved as a standalone treatment for cancer, it has been authorized for emergency use in specific situations, such as during the COVID-19 pandemic, due to its potential antiviral properties. Its use in cancer remains investigational, and approval will depend on the results of ongoing clinical trials.
